Prozomix, a UK-based biotech company focused on novel biocatalyst discovery and manufacturing, and Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, have partnered to build out the production of next generation enzyme plates for active pharmaceutical ingredient (API) manufacturing.
 
This collaboration aims to leverage Ginkgo’s Enzyme Services and industry-leading AI/ML models along with Prozomix’s existing enzyme libraries and deep experience manufacturing enzyme plates.
 
This agreement also marks Prozomix’s entry into the Ginkgo Technology Network, an ecosystem of technology partners dedicated to driving innovation in customer R&D programs. Ginkgo’s Technology Network brings together a diverse array of partners, spanning AI, genetic medicines, biologics, and manufacturing, to integrate their capabilities to provide customers with robust end-to-end solutions for successful R&D outcomes. With Prozomix now in the Technology Network, Ginkgo customers will have access to Prozomix’s scalable contract manufacturing services, including enzyme samples from mg to kg scale.

Creating Best-in-Class Enzymes for API Manufacturing

Prozomix and Ginkgo are partnering to usher in a new generation of biocatalysts built off of sequences and activity data from previous enzyme libraries. Ginkgo will build class-specific AI models informed by enzyme sequences and data from its massive metagenomic database as well as Prozomix’s enzyme libraries and associated screening data. These models can then be used to discover novel functional enzyme sequences. Prozomix intends to then use next-gen enzyme libraries, designed by these models, to manufacture novel enzyme plates.
 
Together, the partners expect these next-gen enzyme plates to have a diversity and performance that traditional plates lack, potentially unlocking biocatalytic opportunities where previous plates have failed. These plates will be freely available to all pharma process chemistry groups, provided that screening data is shared back with Ginkgo to drive further refinement of the Ginkgo AI/ML models.
 
Simon J. Charnock, CEO of Prozomix, said: “With a global reputation for de-risking early stage biocatalytic processes, we believe the Ginkgo partnership will keep Prozomix at the forefront of best-in-class biocatalyst provision throughout the AI revolution, enabling our customers to continue saving and improving more lives.”
 
Cindy Chang, Senior Director, Business Development at Ginkgo Bioworks, added: “API manufacturing is poised to greatly benefit from the latest in enzyme engineering and AI/ML enzyme models. We are so excited to partner with Prozomix to get enzymes into as many API routes as possible and help partners meet both their COGs savings and sustainability goals.”

More Ginkgo Bioworks News

Ginkgo Bioworks recently acquired Modulus Therapeutics’ cell therapy platform assets, including their chimeric antigen receptor (CAR) and switch receptor libraries.